Web Story
Colossal Biosciences, a company focused on de‑extinction and genetic engineering, is reportedly in fundraising talks. Sources say the firm aims to secure new capital at a valuation between
Colossal Biosciences, a company focused on de‑extinction and genetic engineering, is reportedly in fundraising talks. Sources say the firm aims to secure new capital at a valuation between
$20 billion and $30 billion. The prospective valuation would place the company among the highest‑valued biotech startups. Ben Lamm, the co‑founder and chief executive officer, is leading
the effort. The capital raise is intended to fund ongoing research and development programs. Investors are said to be evaluating the company’s long‑term scientific roadmap. A successful round
could accelerate projects targeting extinct species revival. The market will watch for any official announcement in the coming weeks.